Article Details
Retrieved on: 2021-02-17 12:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
“High-quality therapeutic target identification has remained a vexing bottleneck in drug discovery,” said Stephen Elledge, Ph.D., ImmuneID co-founder, ...
Article found on: dc.citybizlist.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here